Previous 10 | Next 10 |
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
LEXINGTON, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennife...
Penny Stocks To Buy On Robinhood, Webull, Fidelity & Others To Watch This Week Penny stocks are some of the most volatile asset classes in the stock market today. But thanks to the growing interest in things like crypto and options, retail traders have pushed risk aside in exchange ...
Agenus announced a licensing deal with Bristol-Myers Squibb. Balstilimab latest data is positive and the BLA is filed with the FDA. With likely approvals and milestone payments, Agenus is on path to become a pharma powerhouse. For further details see: Agenus/Bristol-Myer...
The biotech industry has witnessed solid growth over the past year, in large measure attributable to the demand for drugs to fight COVID-19, among other diseases. The integration of technology and successful clinical trials of drugs for treating critical ailments have boosted Wall Street ...
Palm Beach, FL – May 20, 2021 – In the race against emerging coronavirus variants, researchers are looking beyond antibodies for clues to lasting protection from COVID-19. Concerns about coronavirus variants that might be partially resistant to antibody defenses have spurred r...
Agenus (AGEN) announced new data for balstilimab, an anti-PD-1 antibody, and AGEN2373, a CD137 agonist antibody as contained in abstracts that will be part of two poster presentations scheduled at the American Society for Clinical Oncology ((ASCO)) Annual Meeting 2021.In a Phase 2 trial ...
LEXINGTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced data on the d...
Top Biotech Penny Stocks to Watch Right Now With Bitcoin Price Dipping Below $40,000 While most penny stocks and blue chips are having a rough day, there are always some big gainers to look at. With penny stocks , we often see steep rises even when overall markets are down. And this...
Biotech stocks are officially in a slump. After a rip-roaring 2020 fueled by the advent of COVID-19 vaccines and therapeutics, the iShares Nasdaq Biotechnology ETF has now lost 10% of its value in the past three months. The industry has suddenly lost favor with investors because of ...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...